Essentials of Good Pain Care | AMA STEPS Forward | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Essentials of Good Pain CareA Team-Based Approach

Learning Objectives
1. Explain chronic pain and how pain-related issues have attributed to the opioid epidemic
2. Identify the importance of engaging those providing team-based care including the patient when treating acute or chronic pain
3. Describe how to assess a patient's need for pain control and safely initiate opioid treatment
4. Discuss the importance of monitoring patients on chronic opioid therapy and implementing strategies to mitigate risk
0.5 Credit CME
How will this module help you and your practice develop a safe approach to treating adults with pain outside of active cancer treatment, palliative care and end-of-life care?

  1. Six STEPS to improve the safety of acute and chronic pain treatment

  2. Answers to common questions about treating patients with pain

  3. Downloadable tools you can use in your office


Quiz Ref IDPain-related concerns account for up to 20 percent of all outpatient visits in the United States.1 In 2016, an estimated 6.3 percent of the population was receiving treatment with long-acting opioids, 27 percent of people received at least a one-month supply of opioids. Overall, 66.5 opioid prescriptions were written for every 100 persons.2 There is no single underlying cause for the current “opioid epidemic”, however driving factors include the illicit activity of pill mills, misuse of opioid analgesics, and a chronic lack of treatment for opioid use disorder (OUD). Drug overdose (particularly from illicit fentanyl and heroin) is now the leading cause of death in people under 50 years of age in the United States.3 Improving access to overall pain management, access to comprehensive pain care, and judicious prescribing are a few of the solutions to this public health emergency.

Box Section Ref ID


  • What is chronic pain?

    Chronic pain is defined by the Centers for Disease Control and Prevention (CDC) as pain that lasts for greater than three months or beyond the time of normal tissue healing.4 Estimates of the overall prevalence of chronic pain vary, but recent data suggest that more than 10 percent of adults in the United States report having daily pain, with higher rates among the elderly.5

  • What are the risks of long-term opioid use?

    Opioids can have serious adverse effects, including overdose and death. Long-term use of opioids can result in tolerance, dependence, addiction, and OUD. Opioid use during pregnancy can result in poor pregnancy outcomes including fetal anomalies, premature labor, and neonatal opioid withdrawal syndrome. Opioids may reduce the probability of chronic pain resolution.6

  • Is there evidence for the benefits of long-term opioid use?

    Although more studies are needed, recent evidence suggests that for some patients, discontinuing long-term opioid therapy may actually improve pain, function, and quality of life.10 Multiple meta-analyses have demonstrated that chronic opioid therapy provides little benefit to patients.79

  • What is opioid use disorder (OUD)?

    OUD is a problematic pattern of opioid use leading to clinically significant impairment or distress. Specific criteria for OUD include two or more of the following over a 12-month period, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5):

    • Using larger amounts of opioids or over a longer period than was intended

    • Persistent desire to cut down or unsuccessful efforts to control use

    • Great deal of time spent obtaining, using, or recovering from use

    • Craving, or a strong desire or urge to use substance

    • Failure to fulfill major role obligations at work, school, or home due to recurrent opioid use

    • Continued use despite recurrent or persistent social or interpersonal problems caused or exacerbated by opioid use

    • Giving up or reducing social, occupational, or recreational activities due to opioid use

    • Recurrent opioid use in physically hazardous situations

    • Continued opioid use despite physical or psychological problems caused or exacerbated by its use

    • Tolerance (marked increase in amount, marked decrease in effect)

    • Withdrawal syndrome as manifested by cessation of opioids or use of opioids (or a closely related substance) to relieve or avoid withdrawal symptoms

  • What about using opioids to treat acute pain?

    Many acute pain conditions can be treated with non-opioid therapy. Limiting exposure to opioids for acute pain is considered an important strategy to minimize the development of OUD in those who are susceptible (see Step 4). If opioids are required, many conditions do not require more than a few days of opioid therapy.1 A recent systematic review showed that more than half of opioids prescribed for acute pain go untaken, and the unused pills are rarely stored safely.11 These unused pills can be potentially diverted to inappropriate use. Over half of those who misuse opioids get them from a family or friend for free.12

    A patient's risk for long-term use of opioids has been correlated with the characteristics of initial prescriptions.13,14 For example, in one study, the CDC reported that the rate of long-term opioid use one year after therapy was 6.0 percent for persons with at least one day of opioid therapy, but increased to 13.5 percent when the first episode of use was ≥8 days and 29.9 percent when the first episode of use was ≥31 days.13

Six STEPS to improve the safety of pain treatment in your practice

  1. Engage the team

  2. Engage the patient

  3. Assess the patient

  4. Use non-pharmacologic and non-opioid therapies first

  5. Initiate opioids safely

  6. Monitor the patient

Step 1 Engage the team

Quiz Ref IDIt is important to make sure that everyone in the practice is committed to safety as a primary concern when treating acute or chronic pain. This will involve developing practice-based policies that allow for some standardization of procedures when it comes to pain treatment, particularly with opioids. Examples of practice-based policies include use of prescription drug monitoring program (PDMP) data, if available, maintaining a registry of all patients on chronic opioids within the practice, and instituting an opioid refill policy. More information on each of these components is provided below.

Use available resources to educate the team on opioids

The following resources are highlighted within this module:

Box Section Ref ID


  • What is a prescription drug monitoring program (PDMP)?

    A PDMP is a database of controlled substances that are dispensed by pharmacies in each state (with a few exceptions, including Veterans Administration prescriptions). A list of state PDMP websites can be found here. Reviewing the PDMP allows physicians to identify the controlled substances that have been dispensed to a patient, or if potentially hazardous drug interactions may exist (e.g., between opioids and benzodiazepines).

  • How should the PDMP be used?

    Physicians can use their state PDMP to make more informed treatment decisions. For some patients, it may make sense to check the PDMP every three to six months, for others, it may be appropriate to check with each prescription renewal. Physicians should also become familiar with their state laws about checking the PDMP, as this is mandatory in certain states and the mandated frequencies may differ. Some electronic health records (EHR) have PDMP data integrated into them.

    In certain states, physicians can delegate PDMP access to nurses or medical assistants; those team members can access patient PDMP reports as a part of pre-visit planning. However, some states require prescribers to access the PDMP report themselves.

  • What is an opioid registry?

    Some practices build and maintain a registry of all patients in the practice who are on chronic opioid therapy. Such a registry can be employed to track the use of alternative therapies, referrals to physical therapy, imaging studies done, use of urine drug tests, use of PDMP data, and follow-up visits.

  • What should an opioid reauthorization policy include?

    An opioid reauthorization policy should be established by the practice to maintain consistent risk and safety messages for patients. Your practice can agree on answers to some common questions:

    • Will patients need office visits for opioid reauthorizations?

    • If a visit is required for opioid reauthorization, can that visit be with a nurse?

    • Can a patient pick up an opioid prescription at the front desk?

    • How will reauthorization requests after office hours or on weekends be handled?

    It is important that your practice's policies are consistent with state law and specialty guidelines or recommendations, which in some cases may be contradictory. Your state medical society may be a resource for the latest information.

  • What if I am concerned about patient satisfaction scores for the practice?

    Physicians should make treatment decisions based on their own professional judgement and their patients' best interests. Physician-patient communication is the most important factor related to patient satisfaction with treatment recommendations. Listen and respond with empathy when discussing patient preferences and values. In many instances, communication, not prescribing, is the key to patient satisfaction.

Step 2 Engage the patient

When it comes to pain management, patients need to feel heard. Quiz Ref IDCommunicating with patients includes listening to their stories and acknowledging their pain, while also educating them about the nature of chronic pain in a way that is not patronizing or dismissive.

Useful phrases can include:

  • Tell me more about how this pain impacts your life.

  • What are your goals for therapy?

  • What would you like to be able to do that you are not doing now because of pain?

  • You may always have some pain. One of our goals is to help you manage it safely and maximize your function.

  • Gentle daily exercise may help to decrease your pain.

  • While we may not be able to completely cure your pain, our goal is to make it so the pain doesn't keep you from achieving some of your goals in life.

Box Section Ref ID


Step 3 Assess the patient

Many physicians have been taught to assess patients' pain using the numeric pain intensity scale ranging from 0 to 10, and some may have understood the goal of treatment to be reduction of pain to zero.

Current assessment tools can obtain a more complete picture of patient pain by assessing functional status and emotional well-being. A scale developed by the Department of Defense and Department of Veterans Affairs called the Defense and Veterans Pain Rating Scale (DVPRS) is an enhanced version of the original 0 to 10 pain scale that includes components of functional status, mood, stress, sleep, and activity level. A provider-focused video further explaining this pain scale can be found here. Another tool is the PEG scale for pain assessment and follow-up.

Box Section Ref ID


  • Using a pain assessment tool at every visit will take time. How can I include this in each visit?

    Several systematic approaches can help the team routinely identify patients in need of pain assessment.

    • Banners in the EHR can be used to highlight to physicians and staff that a patient is receiving an opioid analgesic, and signal to rooming staff to provide a pain assessment questionnaire.

    • Rooming staff can be empowered to identify chronic opioid prescriptions during medication reconciliation, triggering an automatic pain assessment questionnaire.

    • List “Chronic Pain Disorder” on the problem list. This, too, can be a flag for the rooming staff to provide the pain assessment questionnaire.

    • A separate visit type can be created for patients with chronic pain who are being treated with opioids, and pain assessment can be included as a routine part of the rooming protocol. During pre-visit planning, these patients can be identified and asked to complete a pain assessment questionnaire upon check-in.

  • For patients on chronic opioid therapy, how can I assess their risk of opioid use disorder (OUD)?

    Every patient prescribed opioids should be assessed for risk of opioid misuse before initiating treatment. The Opioid Risk Tool (ORT) takes less than one minute to administer and can be helpful in identifying patients with higher risk for developing OUD.

    The level and frequency of opioid monitoring depends on the patient's initial risk evaluation. Ongoing evaluation also helps determine whether the benefits of treatment outweigh the risks.

    Note: While outside the scope of this module, naloxone co-prescribing should be considered for patients who are at an increased risk of respiratory depression. Further information can be found here.

  • What factors are associated with patients at high-risk of opioid use disorder (OUD)?

    Although no one is immune to developing OUD, factors more predictive of developing opioid dependence or OUD include a personal history of substance use disorder (with either illicit or prescription drugs), alcohol or nicotine use, a family history of substance use disorder, legal history such as a DUI citation or incarceration, higher daily dose and longer duration of opioid therapy, presence of a mental health disorder, higher rate of utilization of medical and psychiatric services, and history of preadolescent sexual abuse.19 Findings on the relationship between age and risk of OUD vary.

  • Should I screen for depression in patients with chronic pain?

    Yes. Available evidence suggests that 50 to 80 percent of patients with chronic pain also suffer from depression.15,16 Depression can exacerbate pain, which is why antidepressants are often effective for chronic pain treatment. Compared with patients without depression, patients with pain and depression have significantly poorer quality of life, greater somatic symptom severity, a higher prevalence of panic disorder, and a six-fold higher prevalence of anxiety disorders. These patients also have a poorer adherence to treatment, worse satisfaction with treatment, higher likelihood of relapse and less chance for functional improvement.

    For these reasons, it is important that any patient on long-term opioid therapy be screened regularly for depression and, if present, treated appropriately. The PHQ-2, followed by a PHQ-9 if positive, is a good instrument to use for depression screening. The GAD-2 or GAD-7 are good screening instruments for anxiety.

  • What tools are available to assess patient risk?

    There is no single “gold standard” risk assessment tool; however, several tools have been used in practice:

    • ORT: Opioid Risk Tool

    • SOAPP: Screener and Opioid Assessment for Patients with Pain

    • STAR: Screening Tool for Addiction Risk

    • SISAP: Screening Instrument for Substance Abuse Potential

    • PDUQ: Prescription Drug Use Questionnaire

    Providers should not rely on these as the sole determinant of risk; they should be used in the context of overall risk based on individual patient interactions and medical history. It is also important to recognize that estimating a risk profile is a dynamic process, and can change when a patient misses an appointment, loses his/her medication, exhibits other aberrant behaviors, or has unexpected findings in a toxicology or urine drug test.

  • Why is it unsafe to prescribe opioids and benzodiazepines?

    The risk of respiratory suppression increases when opioids and benzodiazepines are used together. Over 30 percent of overdoses involving opioids also involve benzodiazepines. Both types of drugs cause sedation, impair cognition and suppress breathing, which can be fatal.17

Are there additional tools available?

Step 4 Consider non-pharmacologic and non-opioid treatment options

When weighing risks versus benefits, consider the use of non-pharmacologic and non-opioid treatments such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, various physical modalities, cognitive-behavioral therapy, meditation, mindfulness, movement-based therapies, and various forms of exercise therapy. In some cases, surgical or other interventions may be an appropriate consideration as well.

There is a limited but growing body of evidence for using non-opioid treatments for various types of pain.1 For neuropathic pain, topical lidocaine patches, duloxetine, venlafaxine, tricyclic antidepressants, gabapentin, and pregabalin are front-line therapies. Patients with fibromyalgia may experience fewer symptoms with selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SSNRIs), strength training, aquatic exercise therapy, aerobic exercise, and cognitive behavioral therapy. Physical therapy, Tai Chi, acupuncture, and topical NSAIDs can reduce pain in those with osteoarthritis pain. NSAIDs, exercise therapy, massage, Pilates and yoga can reduce pain in those with low back pain. The CDC Fact Sheet provides further information on several non-opioid treatments for chronic pain.

Step 5 Initiate opioids safely

Quiz Ref IDThe decision to use opioids to treat pain is one that requires careful deliberation and detailed conversations between the physician and patient. Long-term opioid therapy often begins with treatment of acute pain. If opioids are indicated, start low and go slow. The lowest effective dose of immediate-release opioids for the shortest therapeutic duration should be prescribed; often three days is sufficient.1

A checklist is helpful for the initial evaluation of patients with chronic pain.

Important components of a checklist include:

  • Setting realistic goals for pain and function

  • Discussing benefits and risks of long-term opioid use

  • Evaluating the risk for opioid misuse

  • Having an exit strategy in place for discontinuing opioid therapy

A patient agreement (example here) can be used to guide the conversation.

Box Section Ref ID


  • Are there ways to use the EHR to assist physicians in changing their prescribing habits?

    Yes. As an example, some organizations have used the EHR to lower the default number of pills prescribed in the emergency room for a new opioid prescription.

  • What can I do for a patient at high risk of OUD with chronic pain?

    Providers can consider finding an alternative therapy to opioids in high-risk patients. Explain to patients who are high-risk that their safety is always the number one concern. Offer alternatives to opioid therapy as described in Step 4. For high-risk patients in whom the physician and the patient decide the benefit of opioids outweighs the risk, extra monitoring and risk mitigation strategies should be utilized, including more frequent toxicology testing, naloxone co-prescription, consideration of pill counts, shorter duration of prescriptions, and more frequent follow-up visits.

    Providers can watch for unexpected changes in the patient's risk profile and consider discontinuing opioid therapy when a patient's risk/benefit ratio increases. Conversations regarding changes in the risk profile of patients on chronic opioids are usually best done in person rather than by EHR messaging or telephone. If there are any other acute or chronic medical conditions—such as hypertension, diabetes or heart disease—that need to be addressed at the visit, these medical conditions should be addressed first. Changes in the risk profile should generally be discussed last.

    In broaching changes in risk profile with the patient, be direct, nonconfrontational and nonjudgmental. Use objective language such as “The PDMP shows you received” rather than “you received.” For example, you can say, “I ran your report in our state database. It shows that in the past month you received four opioid prescriptions from four different providers. Can you help me understand this?”

    Use information from the PDMP or urine drug test results as a way to start the conversation and an opportunity to provide treatment for any potential OUD or other substance use disorder. The conversation should be framed in terms of risk versus benefit. For example, you can say, “Unfortunately, at this point, the risks of chronic opioids exceed the benefits. We still want to help you with your chronic medical conditions and we want to treat your pain. We would recommend a more comprehensive approach that includes physical therapy, pain management, psychiatry, surgical consultation, and non-opioid medicines. We will work with you to control your pain and hope you will work with us.”

  • Why use a patient agreement for chronic opioid therapy?

    Pain care agreements provide an opportunity for informed consent and articulating a plan of care, and can serve as a patient counseling document. Patient agreements can help start a conversation and ensure that the patient and prescriber's expectations are clear. Patient agreements can be signed or just agreed upon verbally, depending on your practice's preference. It is useful to have an agreed upon set of guidelines to refer back to when you must address things such as missed appointments, lost medications, or unexpected urine drug test results. You and your practice can decide how to respond when expectations are not met and how often the agreement should be reviewed and/or signed.

  • When initiating opioids, should I use an immediate-release or extended-release/long-acting formulation?

    There is increased potential for adverse effects from extended-release/long-acting opioids. It is better to initiate therapy with an immediate-release/short-acting agent that can be more easily titrated. In addition, most extended-release/long-acting opioids are only indicated in opioid-tolerant patients, and not for initial therapy.

  • What is an MME?

    The potency of opioids is typically compared to a 10-mg parenteral dose of morphine. Morphine milligram equivalents (MME) are estimated equianalgesic doses of other opioid analgesics compared to morphine. Various equianalgesic conversion tables and calculators exist. Comparative values should be considered approximations only, as they can be affected by interpatient variability, type of pain (i.e., acute vs. chronic), chronicity of treatment, tolerance, and incomplete cross-tolerance between various opioids. MME calculators are available online, here.

Step 6 Monitor the patient

Regular follow-up visits are appropriate for patients on chronic opioid therapy. These visits are used to assess for adverse events and changes in risk of OUD, as well as progress towards treatment goals. The structure of care and intensity of monitoring should be determined based on perceived risk.

Quiz Ref IDRisk mitigation strategies can include:

  • Regular clinic visits

  • Toxicology testing (generally urine or oral fluid)

  • Prescription drug monitoring program (PDMP) checks

A checklist is very helpful for navigating follow-up visits with a patient on chronic opioid therapy. The CDC also provides a comprehensive checklist. Pre-visit planning and registry maintenance by the team in support of these visits is important (see Step 1).

Box Section Ref ID


  • How often should I see a patient who is on chronic opioid therapy?

    A regular follow-up visit is recommended approximately every three months to discuss risks and benefits of opioids. Visits can be conducted more frequently in higher-risk patients.

  • What is the role of urine drug testing in monitoring of patients receiving opioid therapy?

    Urine drug testing is a key monitoring component to ensure that the patient is taking the medication as prescribed. Urine drug tests can be helpful in two ways. First, a negative urine drug test in a patient who is supposed to be on chronic opioid therapy would raise concerns about possible drug diversion. Second, finding illicit substances or other controlled substances that were not prescribed would change the risk profile for the patient. Urine drug testing can help facilitate important conversations with the patient.

  • How accurate is toxicology testing?

    Interpreting these tests requires an understanding of testing modalities, detection times for specific drugs and common explanations for false-positive, false-negative and unexpected results. Results should be interpreted in the context of the patient's entire history.20

    Please see the My Top Care tool from the AMA Council on Science and Public Health for more information. This online tool can help you interpret the urine drug test.

  • How can patients safely dispose of unused medicines?

    Information from the FDA on how to safely dispose of unused medicines can be found here.


Addressing the opioid epidemic calls for physician leadership, creativity and initiative. Physicians and their practices should make this issue a top priority. Recognizing and treating OUD is a crucial component. With the materials provided in this module, physicians and their practices can work together to more safely manage chronic pain in partnership with their patients.

Box Section Ref ID
Graphic Jump Location
AMA Pearls

AMA Pearls

Focus on the big picture

The treatment of chronic pain should not focus on reduction of the pain level to zero, but rather on maximizing overall quality of life and emotional and functional well-being for patients.

Minimize risk

As with other medical interventions, the treatment of chronic pain, including the prescription of opioids, should be considered in terms of risk versus benefit.

Sign in to take quiz and track your certificates

STEPS Forward™ presents actionable, practical toolkits and customizable resources that you can use to successfully implement meaningful and transformative change in your practice or organization. See How it Works

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;

0.5 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;

0.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program; and

0.5 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program;

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Article Information

AMA CME Accreditation Information

Designation Statement: The American Medical Association designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Author Affiliations:

  • Jason Fodeman, MD, MBA, Assistant Professor and Associate Medical Director, Drexel University; Michael McNett, MD, Medical Director for Chronic Pain, Aurora Healthcare GMS, Member, WI Medical Society Task Force, Co-Chair, WI Healthcare Coalition to Reduce Opioid Abuse; Christine Sinsky, MD, FACP, Vice President, Professional Satisfaction, American Medical Association; Daniel P. Alford, MD, MPH, Professor of Medicine, Director, Safe and Competent Opioid Prescribing Education Program, Boston University School of Medicine, Boston Medical Center; Laura J. Zimmermann, MD, MS, FACP, Assistant Professor of Preventive Medicine and Internal Medicine, Rush University; Marie T. Brown, MD, FACP, Associate Professor, Rush University, Senior Advisor Professional Satisfaction and Practice Sustainability, American Medical Association


  • Sean Mackey, MD, PhD, Chief of the Division of Pain Medicine and Redlich Professor of Anesthesiology, Perioperative and Pain Medicine, Neurosciences and Neurology at Stanford University; Immediate Past President, American Academy of Pain Medicine; Sarah Wakeman, MD, Medical Director, Substance Use Disorders Initiative, Program Director, Addiction Medicine Fellowship, Assistant Professor of Medicine, Harvard University; Bernadette Lim, Strategic Project Administrator, Professional Satisfaction and Practice Sustainability, American Medical Association

Disclosure Statement:

  • The content of this activity does not relate to any product or services of a commercial interest as defined by the ACCME; therefore, neither the planners nor the faculty have relevant financial relationships to disclose.

  • The project described was supported by Funding Opportunity Number CMS-1L1-15-002 from the U.S. Department of Health & Human Services, Centers for Medicare & Medicaid Services. The contents provided are solely the responsibility of the authors and do not necessarily represent the official views of HHS or any of its agencies.

Institute of Medicine Committee on Advancing Pain Research, Care, and Education. (2011)  Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Academies Press (US). Retrieved from
Centers for Disease Control and Prevention. (2017).  National Center for Injury Prevention and Control.  Annual Surveillance Report of Drug-Related Risks and Outcomes. Atlanta, GA. Retrieved from Scholar
Rudd  RA, Seth  P, David  F, Scholl  L. (2016)  Increases in drug and opioid-involved overdose deaths—United States, 2010–2015.  Morbidity and Mortality Weekly Report, 65, 1445–1452. doi:10.15585/mmwr.mm655051e1Google ScholarCrossref
Dowell  D, Haegerich  TM, Chou  R. (2016).  CDC guideline for prescribing opioids for chronic pain—United States.  JAMA, 315(15), 1624–1645. doi:10.1001/jama.2016.1464Google ScholarCrossref
Nahin  RL. (2012).  Estimates of pain prevalence and severity in adults: United States.  Journal of Pain, 16(8), 769-780. doi:10.1016/j.jpain.2015.05.002Google ScholarCrossref
Sjøgren  P, Grønbæk  M, Peuckmann  V, Ekholm  O. (2010).  A population-based cohort study on chronic pain: The role of opioids.  The Clinical Journal of Pain, 26(9), 763–769. doi:10.1097/AJP.0b013e3181f15dafGoogle ScholarCrossref
Eisenberg  E, McNicol  ED, Carr  DB. (2005).  Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials.  JAMA, 293(24), 3043–3052. doi:10.1001/jama.293.24.3043Google ScholarCrossref
Ballantyne  JC, Mao  J. (2003).  Opioid therapy for chronic pain.  New England Journal of Medicine, 349(20), 1943–1953. doi:10.1056/NEJMra025411Google ScholarCrossref
Furlan  AD, Sandoval  JA, Mailis-Gagnon  A, Tunks  E. (2006) , Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects.  CMAJ: Canadian Medical Association Journal, 174(11), 1589–1594. doi:10.1503/cmaj.051528Google ScholarCrossref
Frank  JW, Lovejoy  TI, Becker  WC, Morasco  BJ, Koenig  CJ, Hoffecker  L, Dischinger  HR, Dobscha  SK, Krebs  EE. (2017).  Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: A systematic review.  Annals of Internal Medicine, 167, 181–191. doi:10.7326/M17-0598Google ScholarCrossref
Bicket  MC, Long  JJ, Pronovost  PJ, Alexander  GC, Wu  CL. (2017).  Prescription opioid analgesics commonly unused after surgery: A systematic review.  JAMA Surgery, 152(11), 1066–1071. doi:10.1001/jamasurg.2017.0831.Google ScholarCrossref
Substance Abuse and Mental Health Services Administration. (2014)  Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings,  NSDUH Series H-48, HHS Publication No. (SMA) 14-4863.  Rockville, MD. Retrieved from Scholar
Shah  A, Hayes  CJ, Martin  BC. (2017).  Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015.  Morbidity and Mortality Weekly Report, 66(10), 265-269. doi:10.15585/mmwr.mm6610a1Google ScholarCrossref
Barnett  ML, Olenski  AR, Jena  AB. (2017).  Opioid-prescribing patterns of emergency physicians and risk of long-term use.  New England Journal of Medicine, 376(7), 663-673. doi:10.1056/NEJMsa1610524Google ScholarCrossref
Emery  PC, Wilson  KG, Kowal  J. (2014).  Major depressive disorder and sleep disturbance in patients with chronic pain.  Pain Research and Management, 19(1), 35–41. Retrieved from ScholarCrossref
Poole  H, White  S, Blake  C, Murphy  P, Bramwell  R. (2009).  Depression in chronic pain patients: prevalence and measurement.  Pain Practice, 9(3), 173–180. doi:10.1111/j.1533-2500.2009.00274Google ScholarCrossref
National Institute on Drug Abuse. (2018)  Benzodiazapines and Opioids. Retrieved from
Chang  AK, Bijur  PE, Esses  D, Barnaby  DP, Baer  J. (2017).  Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: A randomized clinical trial.  JAMA, 318(17), 1661–1667. doi:10.1001/jama.2017.16190Google ScholarCrossref
Webster  LR. (2017)  Risk factors for opioid-use disorder and overdose.  Anesthesia & Analgesia, 125(5), 1741–1748. doi: 10.1213/ANE.0000000000002496Google ScholarCrossref
Standridge  JB, Adams  SM, Zotos  AP. (2010)  Urine drug screening: A valuable office procedure.  American Family Physician, 81(5), 635–636. Retrieved from Scholar

Name Your Search

Save Search

Lookup An Activity



My Saved Searches

You currently have no searches saved.